Protalex, Inc. focuses on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, a formulation of a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PRTX
CUSIPN/A
Phone215-862-9720
Debt
Debt-to-Equity Ratio-1.66
Current Ratio2.03
Quick Ratio2.03
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.76) per share
Price / Book-0.66
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-4,560,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-654.38%
Miscellaneous
Employees2
Outstanding Shares47,330,000
Protalex (OTCMKTS:PRTX) Frequently Asked Questions
What is Protalex's stock symbol?
Protalex trades on the OTCMKTS under the ticker symbol "PRTX."
How were Protalex's earnings last quarter?
Protalex Inc. (OTCMKTS:PRTX) released its quarterly earnings results on Friday, April, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. View Protalex's Earnings History.
When is Protalex's next earnings date?
Who are some of Protalex's key competitors?
Some companies that are related to Protalex include Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), US Stem Cell (USRM), Tenax Therapeutics (TENX), ALGAE TEC Ltd/S (ALGXY), Geovax Labs (GOVX) and Redpoint Bio (RPBC).
Who are Protalex's key executives?
Protalex's management team includes the folowing people:
- Mr. Arnold P. Kling Esq., Pres and Director (Age 60)
- Mr. Kirk M. Warshaw, Chief Financial Officer, Sec. and Director (Age 60)
- Dr. William E. Gannon JR., M.D., M.B.A., Chief Medical Officer & Member of Scientific Advisory Board
- Dr. John Bruce Lundy McClain M.D., Medical Director & Member of Scientific Advisory Board
- Dr. Richard J. Francovitch Ph.D., VP of ITP Program & Member of Scientific Advisory Board
Has Protalex been receiving favorable news coverage?
Headlines about PRTX stock have been trending somewhat negative on Wednesday, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Protalex earned a news sentiment score of -0.02 on Accern's scale. They also gave headlines about the company an impact score of 40.10 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Protalex?
Shares of PRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalex's stock price today?
One share of PRTX stock can currently be purchased for approximately $0.50.
How big of a company is Protalex?
Protalex has a market capitalization of $23.66 million. Protalex employs 2 workers across the globe.
How can I contact Protalex?
Protalex's mailing address is 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932. The company can be reached via phone at 215-862-9720 or via email at [email protected]
MarketBeat Community Rating for Protalex (PRTX)
MarketBeat's community ratings are surveys of what our community members think about Protalex and other stocks. Vote "Outperform" if you believe PRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
